BCTX - BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
(NewsDirect)
Small and big pharmacompanies such as Pfizer Inc. (NYSE: PFE), CelldexTherapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ:HOLX) are ramping up efforts to help reduce or eliminate the growingbreast cancer mortality rate.
As it stands now, breast cancer is the second most common cause of cancer death in women in the U.S. It is estimated that 43,780people — 43,250 women and 530 men — will die from breast cancerthis year alone.
Globally, female breast cancer is the fifth leading cause ofdeath. An estimated 684,996 women worldwide died from breast cancer in2020, with metastatic breast cancer causing the vast majority of thedeaths.
Theincreasing death rate has led companies like BriaCell TherapeuticsCorp. (NASDAQ: BCTX) (NASDAQ: BCTXW) (TSX: BCT) to advanceresearch and development into therapies that could prove moreeffective against breast and other cancers.
Focusing initially onbreast cancer, BriaCell isdedicated to enhancing the lives of people with cancer with limitedtherapy options by developing novel immunotherapies to fight thedisease.
Immunotherapies have become the forefront of cancer treatmentsbecause they use the body’s immune system to destroy cancer cells,offer the potential for higher levels of safety and efficacy thanchemotherapy and may also prevent cancer recurrence.
BriaCell currently has anon-exclusive clinical trial collaboration with IncyteCorporation (NASDAQ: INCY) to evaluate the effects of combinationsof novel clinical candidates.
BriaCell is currently conducting a Phase I/IIclinical trial of its lead product candidate, Bria-IMT™, incombination with the immunotherapy development candidate retifanlimab,an anti-PD-1 antibody provided by Incyte, for the treatment ofadvanced breast cancer.
Positive Clinical And Quality Of LifeData
On December8, BriaCell presented positive safety/tolerability and efficacy data from its lead productcandidate – Bria-IMT™ – summarized in three poster sessionsduring the 2022 San Antonio Breast Cancer Symposium ®(SABCS).
Summary Of The Positive Data
-
Positive clinical data reported includes tumor shrinkage,disease control, progression-free survival, and potential long-termsurvival benefit in advanced metastatic breast cancer patients treatedwith the Bria-IMT™ combination regimen.
-
“Better quality of life” and “lesspain” reported by many gravely ill advanced metastatic breast cancerpatients treated with the Bria-IMT™ combinationregimen.
-
Notably, manypatients remained in their study longer than other prior therapies,suggesting excellent tolerability and clinical effectiveness of theBria-IMT™ combination regimen.
-
More positive data is expected as patients remain in thestudy.
-
Treatment remained well-tolerated with no dose-limiting toxicities.
The posters aresummarized below and also available to view here: https://briacell.com/scientific-publications/ .
Mayo Clinic Professorand Principal Clinical Investigator Saranya Chumsri, M.D., stated inan audio summary of the poster: “First, this is a heavily pretreatedgroup of end-stage metastatic breast cancer (“MBC”) patients. Formany of these patients, other therapies don’t exist or cannot betolerated.”
“Bria-IMT™ does not have any theoretical cross-resistanceor overlapping toxicity with other MBC treatments, which is why it isso encouraging to see responses across all MBC subtypes and a verymanageable adverse event experience,” he added.
Dr. William V. Williams,BriaCell’s President and CEO, also commenting on the data, said,“We are impressed with the positive clinical and quality of lifedata in this very difficult-to-treat patient population who havefailed multiple prior treatments. We’re delighted that many patientsstayed on our study longer than their last therapy, suggesting theBria-IMT™ combination regimen is both well tolerated and clinicallyeffective.”
According to him, “these results have positive implications,both for our ongoing, randomized phase II study and for plannedmeetings with the U.S. Food and Drug Administration (FDA) on thedesign of our pivotal study. Advanced MBC remains one of the mostdifficult cancers to treat.”
“There remains an urgent, unmet medical need tofind well-tolerated and effective treatments for these gravely illcancer patients who have only months to live and cannot tolerate theharsh side effects of other cancer treatments,” Williamsconcluded.
Read adetailed insight into the positive clinical and quality of life datain advanced metastatic breast cancer here .
BriaCellis an immuno-oncology-focused biotechnology company developingtargeted and effective approaches for the management of cancer.
This post contains sponsored advertising content. Thiscontent is for informational purposes only and is not intended to beinvesting advice.
Contact Details
COREIR
CompanyWebsite
Copyright (c) 2022 TheNewswire - All rights reserved.